0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge |

A Semisynthetic Bilaminar Skin Substitute Used to Treat Pediatric Full-Body Toxic Epidermal Necrolysis FREE

[+] Author Affiliations

Section Editor: George J. Hruza, MD
Assistant Section Editor: Dee Anna Glaser, MD
Assistant Section Editor: Elaine Siegfried, MD

More Author Information
Arch Dermatol. 2004;140(2):160-162. doi:10.1001/archderm.140.2.160.
Text Size: A A A
Published online

REPORT OF A CASE

A 17-month-old immunocompromised girl was admitted to the Children's University Hospital because of anemia and upper airway infection. Six months previously, she had undergone a matched unrelated bone marrow transplantation to treat juvenile myelomonocytic leukemia. Intravenous antibiotic therapy with ceftazidime was started for clinical and laboratory signs of infection.

The following day, the child developed a rapidly spreading bullous exanthema characteristic of toxic epidermal necrolysis (TEN) (Figure 1 and Figure 2) along with respiratory insufficiency requiring artificial ventilation and intensive care. A skin biopsy specimen taken from the trunk revealed a hyperkeratotic epidermis and massive epidermal necrosis with focal regeneration of the basal cell layer (Figure 3), supporting a diagnosis of TEN and ruling out staphylococcal scalded skin syndrome. Findings from an extensive workup to rule out an associated infectious cause were negative except for 1 positive blood culture for Staphylococcus epidermidis, suggesting that the intravenous ceftazidime therapy was the most likely cause.

Place holder to copy figure label and caption
Figure 1.

Two days after admission, the whole body shows a retiform erythema, confluent bullae, and large erosions.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Detail picture of the right lower leg showing large confluent bullae.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Biopsy specimen taken from the edge of a blister. The arrows mark the transition from intact epidermis (E) to necrosis (N) (hematoxylin-eosin, orginal magnification ×100).

Graphic Jump Location

THERAPEUTIC CHALLENGE

Toxic epidermal necrolysis is a painful, full-thickness, exfoliative skin disorder that may involve a large body surface area and mucosae with a high risk of secondary infection. The critical issue of coping with the sequelae of sepsis due to secondary wound infection remains a challenge in the treatment of this condition. After necessary debridement for prevention of infection, an ideal dressing technique would prevent pain and fluid and electrolyte loss and would allow patient mobility without shear stress on the wound.

SOLUTION

Two days after admission, meticulous surgical debridement of the blisters was performed. The whole body surface was then completely wrapped with a semisynthetic bilaminar skin substitute (Biobrane; Dow B. Hickham Inc, Sugarland, Tex) in an all-in-one suitlike manner using skin staples (Auto Suture; US Surgical, Norwalk, Conn) to fix the dressing and the overlapping parts of the material. This treatment has been reported to be helpful in superficial burns and scalds1 and in adults with TEN.2

This semisynthetic material meets some standards of an ideal skin substitute: it is easy to use, provides several beneficial physiologic effects, and improves comfort.3 Since the membrane is stretchable, both trunk and extremities could be covered by "wrapping around" the biomaterial, fixing it with slight tension, and stapling the ends together without skin fixation. Dressing changes with dexpanthenol ointment were only necessary on the face. The wound status was easily monitored owing to the translucency of the skin substitute. General intensive care treatment was guided by the pediatric intensive care unit team, including respiratory therapy, fluid resuscitation, electrolyte balancing, and systemic infection control.

During the 10 next days, the wounds showed consistent healing without signs of new blister formation. The membrane provided excellent adherence and allowed immediate mobilization (Figure 4). Three days postoperatively, the child was extubated. Ten days postoperatively, the skin substitute started to fall off. Reepithelialization was observed by day 12 (Figure 5). Five weeks after operative debridement and wound coverage, the child could return to the daily ward. Six months later, there was no sign of scarring (Figure 6).

Place holder to copy figure label and caption
Figure 4.

Two days after surgery, the semisynthetic bilaminar skin substitute shows excellent adherence to the wounds.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.

Twelve days after surgery, the semisynthetic bilaminar skin substitute has fallen off, and the wounds are completely reepithelialized.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 6.

Lower right leg 6 months after treatment without signs of scarring.

Graphic Jump Location

COMMENT

First described by Lyell4 in1956, TEN is an exfoliative skin disorder that may involve a large body surface area. The microscopic changes are comparable with those that occur in superficial dermal burns. Complications of TEN are related to the loss of the epithelial skin barrier, including fluid, protein, and electrolyte loss and an increased risk of sepsis. Despite recent advances in intensive care of such lesions, the mortality rate remains high, comparable with that of full-body burn lesions.5

Surgical management includes the early debridement of necrotic areas and wound coverage. Several methods have been described to cover the skin lesions, including various ointments, allografts, xenografts, and amniotic membranes.5 A synthetic bilaminar membrane used as a skin substitute (Biobrane) has been shown to decrease pain and hospitalization in superficial second-degree burns.1 Biobrane consists of a custom-knitted nylon fabric mechanically bonded to an ultrathin silicone membrane. The entire dressing is uniformly coated with collagen peptides covalently and independently bonded to the dressing, rendering the dressing hydrophilic and tissue compatible, and it decreases the loss of fluid. The dressing is readily available, nonimmunogenic, and easy to apply, and it renders frequent and painful dressing changes unnecessary. Several authors have described the advantages of this wound coverage in cases of TEN.2,3,6,7

We describe a 17-month-old girl who underwent bone marrow transplantation and subsequentely developed TEN, most likely due to intravenous cephalosporin treatment. Fluid loss was successfully managed with debridement and application of the semisynthetic membrane applied as a body suit. Usually in acute burns, such occlusive dressings are only applied within the first hours after the trauma and after surgical debridement of any skin necrosis. Owing to the potential infection, no secondary applications of this material later than 6 hours after the burn have been reported.

Nevertheless, to avoid the numerous painful dressing changes, we decided to secondarily apply the membrane to our patient after a surgical debridement 2 days after the onset of TEN. No infection occurred, and the healing was uneventful. This is consistent with our experiences in successfully treating numerous scalds in children and adults over the last 7 years with this material.8,9 The rapid healing under this body suit–type dressing without any more dressing changes confirms the positive experiences described by other authors concerning the properties of this material. The present case demonstrates that a total body wrapping with this skin substitute may ameliorate pain and the need for pain medication in cases of TEN.

ARTICLE INFORMATION

Corresponding author: Raymund E. Horch, MD, PhD, Department of Plastic and Hand Surgery, University Hospital of the Friedrich-Alexander-University Erlangen-Nürnberg, Krankenhausstraße 12, D-91054 Erlangen, Germany (e-mail: raymund.horch@chir.imed.uni-erlangen.de).

Accepted for publication May 19, 2003.

The authors have no relevant financial interest in this article.

We thank Norbert Böhm, MD, for histopathologic advice and histologic sections.

Submissions

Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement, as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc, 14377 Woodlake Dr, Suite 111, St Louis, MO 63017.

REFERENCES

Barret  JPDziewulski  PRamzy  PIWolf  SEDesai  MHHerndon  DN Biobrane versus 1% silver sulfadiazine in second degree pediatric burns Plast Reconstr Surg. 2000;10562- 65
PubMed Link to Article
Bradley  TBrown  REKucan  JOSmoot III  ECHussmann  J Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage Ann Plast Surg. 1995;35124- 132
PubMed Link to Article
Sowder  LL Biobrane wound dressing used in the treatment of toxic epidermal necrolysis: a case report J Burn Care Rehabil. 1990;11237- 239
PubMed Link to Article
Lyell  A Toxic epidermal necrolysis: an eruption resembling scalding of the skin Br J Dermatol. 1956;68355- 361
Link to Article
Palmieri  TLGreenhalgh  DGSaffle  JR  et al.  A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century J Burn Care Rehabil. 2002;2387- 96
PubMed Link to Article
Kucan  JO Use of Biobrane in the treatment of toxic epidermal necrolysis J Burn Care Rehabil. 1995;16324- 327
PubMed Link to Article
Arevalo  JMLorente  JA Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis J Burn Care Rehabil. 1999;20406- 410
PubMed Link to Article
Weiß  HHorch  REHimpel  G  et al.  Verbrühungen und Verbrennungen im Kindes und Jugendalter: funktionelle Früh- und Spätresultate nach Anwendung biosynthetischer Hautsubstitute  Paper presented at: 47th annual meeting of the South German Society for Pediatrics and Youth Health Care May 8-10, 1998 Freiburg, Germany
Horch  REBannasch  HKopp  JAndree  CStark  GB Single-cell suspensions of cultured human keratinocytes in fibrin-glue reconstitute the epidermis Cell Transplant. 1998;7309- 317
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Two days after admission, the whole body shows a retiform erythema, confluent bullae, and large erosions.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Detail picture of the right lower leg showing large confluent bullae.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Biopsy specimen taken from the edge of a blister. The arrows mark the transition from intact epidermis (E) to necrosis (N) (hematoxylin-eosin, orginal magnification ×100).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Two days after surgery, the semisynthetic bilaminar skin substitute shows excellent adherence to the wounds.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.

Twelve days after surgery, the semisynthetic bilaminar skin substitute has fallen off, and the wounds are completely reepithelialized.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 6.

Lower right leg 6 months after treatment without signs of scarring.

Graphic Jump Location

Tables

References

Barret  JPDziewulski  PRamzy  PIWolf  SEDesai  MHHerndon  DN Biobrane versus 1% silver sulfadiazine in second degree pediatric burns Plast Reconstr Surg. 2000;10562- 65
PubMed Link to Article
Bradley  TBrown  REKucan  JOSmoot III  ECHussmann  J Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage Ann Plast Surg. 1995;35124- 132
PubMed Link to Article
Sowder  LL Biobrane wound dressing used in the treatment of toxic epidermal necrolysis: a case report J Burn Care Rehabil. 1990;11237- 239
PubMed Link to Article
Lyell  A Toxic epidermal necrolysis: an eruption resembling scalding of the skin Br J Dermatol. 1956;68355- 361
Link to Article
Palmieri  TLGreenhalgh  DGSaffle  JR  et al.  A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century J Burn Care Rehabil. 2002;2387- 96
PubMed Link to Article
Kucan  JO Use of Biobrane in the treatment of toxic epidermal necrolysis J Burn Care Rehabil. 1995;16324- 327
PubMed Link to Article
Arevalo  JMLorente  JA Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis J Burn Care Rehabil. 1999;20406- 410
PubMed Link to Article
Weiß  HHorch  REHimpel  G  et al.  Verbrühungen und Verbrennungen im Kindes und Jugendalter: funktionelle Früh- und Spätresultate nach Anwendung biosynthetischer Hautsubstitute  Paper presented at: 47th annual meeting of the South German Society for Pediatrics and Youth Health Care May 8-10, 1998 Freiburg, Germany
Horch  REBannasch  HKopp  JAndree  CStark  GB Single-cell suspensions of cultured human keratinocytes in fibrin-glue reconstitute the epidermis Cell Transplant. 1998;7309- 317
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

800 Views
11 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs